Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company focused on metastatic breast cancer and neurodegenerative diseases such as ALS. While recent company communications describe its programs and strategy, formal SEC filings offer detailed legal and financial disclosures about these activities.
Through this page, users can review core periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss LeonaBio’s clinical-stage pipeline, risk factors related to drug development, and information about licensing arrangements like its exclusive global license (excluding Asia and certain Middle Eastern countries) for lasofoxifene from Sermonix Pharmaceuticals, Inc. These filings may also describe the company’s private placement financings of common stock and warrants that are intended to support clinical and regulatory milestones.
Investors can also look for current reports on Form 8-K, which are used to disclose material events such as the company’s name change from Athira Pharma, Inc. to LeonaBio, Inc., adoption of the LONA ticker, significant licensing transactions, or financing events. In addition, proxy statements on Schedule 14A and related documents can provide information on corporate governance and executive compensation.
This platform enhances access to LeonaBio’s regulatory history by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These summaries are designed to help readers quickly interpret lengthy documents, highlight key sections related to the company’s oncology and neurodegeneration programs, and make it easier to locate information about capital raises, licensing agreements, and other material disclosures.
LeonaBio, Inc. is registering up to 5,502,402 shares of common stock for resale by Sermonix Pharmaceuticals, Inc., issuable upon exercise of a pre-funded warrant from a December 2025 licensing transaction. LeonaBio will not sell any shares in this offering and receives no resale proceeds.
The company will receive only the nominal cash exercise price of $0.001 per share, or about $5,502 in gross proceeds if the warrant is fully exercised. As of March 16, 2026, LeonaBio had 9,393,514 shares of common stock outstanding, and its stock traded at $8.42 per share on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. is registering up to 58,464,567 shares of common stock for resale by existing investors under a Form S-1 converted from a prior Form S-3. These shares include stock already issued and shares issuable from pre-funded warrants and other warrants held by December 2025 private placement investors.
LeonaBio will not sell any shares in this offering and will not receive proceeds from selling stockholders’ resales. It may receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share, and approximately $146,249,987 from cash exercises of warrants on 23,031,494 underlying shares at $6.35 per share. As of March 16, 2026, 9,393,514 shares of common stock were outstanding, and the stock traded at $8.42 on Nasdaq under the symbol LONA.
LeonaBio, Inc. filed a second amendment to an earlier report to align with SEC guidance treating its Sermonix transaction as an acquisition of a business. The company obtained a waiver from certain financial statement requirements in exchange for providing expanded qualitative and cash expenditure disclosures.
The amendment details historical unaudited cash spending on the ELAINE-3 Study, including about $14 million, $12 million and $5 million by Sermonix in 2023, 2024 and part of 2025, and approximately $11 million by LeonaBio from December 18 through December 31, 2025. LeonaBio now expects to spend about $45 million in 2026 and $30 million in 2027 as it broadens the study scope.
The company has increased the ELAINE-3 Study intensity, expanded the contract research organization’s responsibilities, and plans to raise the sample size from 500 to up to 600 participants. It currently expects to complete enrollment in the fourth quarter of 2026 and release topline data in the second half of 2027.
LeonaBio, Inc. reported full-year 2025 results and highlighted a major strategic shift toward oncology and neurodegeneration. For the year ended December 31, 2025, cash, cash equivalents and investments rose to $88.3 million from $51.3 million, helped by a $90 million private placement of common stock and warrants that could bring in up to an additional $146 million if fully exercised.
Research and development expenses increased to $85.6 million, mainly from $68.1 million of acquired in‑process R&D tied to the lasofoxifene license, while general and administrative expenses fell to $16.7 million. Net loss widened modestly to $105.6 million, or $24.70 per share, compared with $96.9 million, or $25.19 per share, in 2024.
The company acquired an exclusive global license (excluding Asia and certain Middle East countries) to late‑stage breast cancer drug candidate lasofoxifene and is running the Phase 3 ELAINE‑3 trial, expecting enrollment completion in 4Q 2026 and topline data in 2H 2027. Its ALS candidate ATH‑1105 showed favorable Phase 1 safety and CNS penetration, with a Phase 2 proof‑of‑concept study in ALS planned to start in the second half of 2026.
LeonaBio, Inc. reported results of a special stockholder meeting where several major equity actions were approved. Stockholders adopted a new 2026 Equity Incentive Plan allowing issuance of up to 5,700,000 shares, plus up to 1,300,000 additional shares recycled from certain expired or forfeited awards under the prior 2020 plan, and an annual increase tied to up to 5% of outstanding common stock and pre-funded warrants.
Stockholders also approved potential issuances of common stock upon exercise of a Sermonix pre-funded warrant for 5,502,402 shares and additional warrant exercises by Perceptive Advisors that could raise their beneficial ownership above 19.99%, consistent with Nasdaq Rules 5635(a)(2) and 5635(b). In a major capital structure change, authorized common stock increased from 90,000,000 to 400,000,000 shares and total authorized capital stock from 190,000,000 to 500,000,000 shares via a certificate of amendment filed on March 18, 2026.
LeonaBio, Inc. President and CEO Mark James Litton reported several equity transactions involving company stock. On March 3, 2026, 22,254 restricted stock units were exercised at $0.00 per share, converting into the same number of common shares and bringing his direct common stock holdings to 63,082 shares.
On March 4, 2026, 5,156 common shares were sold at a weighted-average price of $5.37 per share to cover tax withholding obligations triggered by the RSU vesting under the company’s mandatory “sell to cover” policies; no additional shares were sold. After this tax-related sale, he directly owned 57,926 common shares. Separate irrevocable trusts established for his children each held 656 common shares as indirect ownership.
LeonaBio, Inc.’s chief financial officer reported routine equity activity involving restricted stock units and a small tax-related sale. On March 3, 3,900 restricted stock units vested and converted into the same number of common shares. On March 4, 906 common shares were sold at a weighted-average price of $5.37 solely to cover tax withholding obligations under a mandatory “sell to cover” policy, leaving 15,851 common shares held directly.
LeonaBio, Inc. executive Mark Worthington reported a mix of share transactions tied to vesting equity awards. On March 3, 2026, 5,726 restricted stock units were exercised into the same number of common shares at $0.00 per share, reflecting a standard RSU conversion.
On March 4, 2026, 1,328 common shares were sold in an open-market transaction at a weighted-average price of $5.37 per share to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, which the filing notes was not a discretionary sale. After these transactions, Worthington directly held 18,376 common shares.
LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.
Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.
After these transactions, Church directly held 25,178 shares of LeonaBio common stock.